High specific activity tritium labelling of some sigma-1 receptor agonists

  • David G. Ahern
  • Richard J. Seguin
  • Crist N. Filer


The high specific activity tritiation of (+)-SKF-10,047 (1) and N,N-dimethyltryptamine (4) is described. [N-allyl-3H] (+)-SKF-10,047 (3) was prepared by Lindlar catalyst tritiation of (+)-N-propargylnormetazocine (2) and [N-methyl-3H] N,N-dimethyltryptamine (6) was synthesized by the alkylation of N-methyltryptamine (5) with [3H] methyl iodide. Both sigma-1 synthetic agonist 3 and endogenous agonist 6 have been useful in studying this receptor.


Sigma-1 receptor Tritium Tritium NMR 



We would like to acknowledge the contributions of Drs. Puliyer Srinivasan and Mahendra Suryan of PerkinElmer Health Sciences Inc. in obtaining the NMR spectra and mass spectra respectively.


  1. 1.
    Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197:517–532Google Scholar
  2. 2.
    Hayashi T, Su T-P (2005) The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol 3:267–280CrossRefGoogle Scholar
  3. 3.
    Narayanan S, Mesangeau C, Poupaert JH, McCurdy CR (2011) Sigma receptors and cocaine abuse. Curr Topics Med Chem 11:1128–1150CrossRefGoogle Scholar
  4. 4.
    Rodvelt KR, Miller DK (2010) Could sigma receptor ligands be a treatment for methamphetamine addiction? Current Drug Abuse Reviews 3:156–162CrossRefGoogle Scholar
  5. 5.
    Van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH, Dierckx RAJO (2010) Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Nucl Med Molec Imag 16:3519–3537Google Scholar
  6. 6.
    Bhuiyan MS, Fukunaga K (2011) Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection. Expert Opin Ther Targets 15:145–155CrossRefGoogle Scholar
  7. 7.
    Fishback JA, Robson MJ, Xu Y-T, Matsumoto RR (2010) Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther 127:271–282CrossRefGoogle Scholar
  8. 8.
    Diaz JL, Zamanillo D, Corbera J, Baeyens JM, Maldonado R, Pericas MA, Vela JM, Torrens A (2009) Selective sigma-1 receptor antagonists: emerging target for the treatment of neuropathic pain. Cent Nerv Sys Agents in Med Chem 9:172–183Google Scholar
  9. 9.
    Hashimoto K (2009) Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia? CNS Neurol Disord: Drug Targets 8:470–474Google Scholar
  10. 10.
    Maurice T, Su T-P (2009) The pharmacology of sigma-1 receptors. Pharmacol Ther 124:195–206CrossRefGoogle Scholar
  11. 11.
    Tsai S-Y, Hayashi T, Mori T, Su T-P (2009) Sigma-1 receptor chaperones and diseases. Cent Nerv Sys Agents Med Chem 9:184–189Google Scholar
  12. 12.
    Cobos EJ, Entrena JM, Nieto FR, Cendan CM, del Pozo E (2008) Pharmacology and therapeutic potential of sigma-1 receptor ligands. Curr Neuropharmacol 6:344–366CrossRefGoogle Scholar
  13. 13.
    Brine GA, Berrang B, Hayes JP, Carroll FI (1990) An improved resolution of (±)-cis-N-normetazocine. J Heterocyclic Chem 27:2139–2143CrossRefGoogle Scholar
  14. 14.
    Brady KT, Balster RL, May EL (1982) Stereoisomers of N-allylnormetazocine: phencyclidine-like behavior effects in squirrel monkeys and rats. Science 215:178–180CrossRefGoogle Scholar
  15. 15.
    Aceto MD, May EL (1983) Antinociceptive studies of the optical isomers of N-allylnormetazocine (SKF-10,047). Eur J Pharmacol 91:267–272CrossRefGoogle Scholar
  16. 16.
    Slifer BL, Balster RL (1983) Reinforcing properties of stereoisomers of the putative sigma agonists N-allylnormetazocine and cyclazocine in Rhesus monkeys. J Pharmacol Exp Ther 225:522–528Google Scholar
  17. 17.
    Zukin SR, Brady KT, Slifer BL, Balster RL (1984) Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res 294:174–177CrossRefGoogle Scholar
  18. 18.
    Ambroise Y, Mioskowski C, Djega-Mariadassou G, Rousseau B (2000) Consequences of affinity in heterogeneous catalytic reactions: highly chemoselective hydrogenolysis of iodoarenes. J Org Chem 65:7183–7186CrossRefGoogle Scholar
  19. 19.
    Faucher N, Ambroise Y, Cintrat J-C, Doris E, Pillon F, Rousseau B (2002) Highly chemoselective hydrogenolysis of iodoarenes. J Org Chem 67:932–934CrossRefGoogle Scholar
  20. 20.
    Lindlar H (1952) Ein neuer katalysator fur selektive hydrierungen. Helv Chim Acta 35:446–450CrossRefGoogle Scholar
  21. 21.
    Tsao L-I, Su T-P (1996) IP3 receptor antagonist heparin uncompetitively inhibits [3H] (+)-SKF-10,047 binding to sigma receptors. Eur J Pharmacol 311:R1–R2CrossRefGoogle Scholar
  22. 22.
    Bouchard P, Roman F, Junien J-L, Quirion R (1996) Autoradiographic evidence for the modulation of in vivo sigma receptor labeling by neuropeptide Y and calcitonin gene-related peptide in the mouse brain. J Pharmacol Exp Ther 276:223–230Google Scholar
  23. 23.
    McCann DJ, Su TP (1991) Solubilization and characterization of haloperidol-sensitive (+)-[3H] SKF-10,047 binding sites (sigma sites) from rat liver membranes. J Pharmacol Exp Ther 257:547–554Google Scholar
  24. 24.
    Kavanaugh MP, Parker J, Bobker DH, Keana JFW, Weber E (1989) Solubilization and characterization of sigma-receptors from guinea pig brain membranes. J Neurochem 53:1575–1580CrossRefGoogle Scholar
  25. 25.
    Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE (2009) The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 323:934–937CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2011

Authors and Affiliations

  • David G. Ahern
    • 1
  • Richard J. Seguin
    • 1
  • Crist N. Filer
    • 1
  1. 1.PerkinElmer Health Sciences, Inc.WalthamUSA

Personalised recommendations